Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN)
- PMID: 20530009
- PMCID: PMC3129620
- DOI: 10.1001/archgenpsychiatry.2010.55
Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN)
Abstract
Context: The contribution of reproductive hormones to mood has been the focus of considerable research. Results from clinical and epidemiological studies have been inconsistent. It remains unclear whether alterations in serum hormone levels across the menopausal transition are linked to depressive symptoms.
Objectives: To evaluate the relationship between serum hormone levels and high depressive symptoms and whether hormone levels or their change might explain the association of menopausal status with depressive symptoms previously reported in a national sample of midlife women.
Design: A longitudinal, community-based, multisite study of menopause. Data were collected at baseline and annually from December 1995 to January 2008 on a range of factors. Early follicular phase serum samples were assayed for levels of estradiol, follicle-stimulating hormone, testosterone, and dehydroepiandrosterone sulfate.
Setting: Seven communities nationwide.
Participants: A community-based sample of 3302 multiethnic women, aged 42 to 52 years, still menstruating and not using exogenous reproductive hormones. Main Outcome Measure Depressive symptoms assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The primary outcome was a CES-D score of 16 or higher.
Results: In multivariable random-effects logistic regression models, log-transformed testosterone level was significantly positively associated with higher odds of a CES-D score of 16 or higher (odds ratio = 1.15; 95% confidence interval, 1.01-1.31) across 8 years, and a larger increase in log-transformed testosterone from baseline to each annual visit was significantly associated with increased odds of a CES-D score of 16 or higher (odds ratio = 1.23; 95% confidence interval, 1.04-1.45). Less education, being Hispanic, and vasomotor symptoms, stressful life events, and low social support at each visit were each independently associated with a CES-D score of 16 or higher. No other hormones were associated with a CES-D score of 16 or higher. Being perimenopausal or postmenopausal compared with being premenopausal remained significantly associated with a CES-D score of 16 or higher in all analyses.
Conclusions: Higher testosterone levels may contribute to higher depressive symptoms during the menopausal transition. This association is independent of menopausal status, which remains an independent predictor of higher depressive symptoms.
Figures


Similar articles
-
Associations of hormones and menopausal status with depressed mood in women with no history of depression.Arch Gen Psychiatry. 2006 Apr;63(4):375-82. doi: 10.1001/archpsyc.63.4.375. Arch Gen Psychiatry. 2006. PMID: 16585466
-
Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN).Psychol Med. 2011 Sep;41(9):1879-88. doi: 10.1017/S003329171100016X. Epub 2011 Feb 9. Psychol Med. 2011. PMID: 21306662 Free PMC article.
-
The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition.J Clin Endocrinol Metab. 2005 Nov;90(11):6106-12. doi: 10.1210/jc.2005-1374. Epub 2005 Sep 6. J Clin Endocrinol Metab. 2005. PMID: 16144949
-
The menopausal transition--endocrinology.J Sex Med. 2008 Oct;5(10):2266-73. doi: 10.1111/j.1743-6109.2008.00921.x. Epub 2008 Jul 1. J Sex Med. 2008. PMID: 18624962 Review.
-
Mood and menopause: findings from the Study of Women's Health Across the Nation (SWAN) over 10 years.Obstet Gynecol Clin North Am. 2011 Sep;38(3):609-25. doi: 10.1016/j.ogc.2011.05.011. Obstet Gynecol Clin North Am. 2011. PMID: 21961723 Free PMC article. Review.
Cited by
-
Distinguishing 6 population subgroups by timing and characteristics of the menopausal transition.Am J Epidemiol. 2012 Jan 1;175(1):74-83. doi: 10.1093/aje/kwr276. Epub 2011 Dec 2. Am J Epidemiol. 2012. PMID: 22138039 Free PMC article.
-
Depression in women with spontaneous 46, XX primary ovarian insufficiency.J Clin Endocrinol Metab. 2011 Feb;96(2):E278-87. doi: 10.1210/jc.2010-0613. Epub 2010 Nov 3. J Clin Endocrinol Metab. 2011. PMID: 21047929 Free PMC article.
-
Prenatal depression and anxiety in Toxoplasma gondii-positive women.Am J Obstet Gynecol. 2011 May;204(5):433.e1-7. doi: 10.1016/j.ajog.2011.01.004. Epub 2011 Feb 23. Am J Obstet Gynecol. 2011. PMID: 21345406 Free PMC article.
-
Perfluoroalkyl Substances and Incident Natural Menopause in Midlife Women: The Mediating Role of Sex Hormones.Am J Epidemiol. 2022 Jun 27;191(7):1212-1223. doi: 10.1093/aje/kwac052. Am J Epidemiol. 2022. PMID: 35292812 Free PMC article.
-
Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.PLoS Med. 2015 Jun 2;12(6):e1001833; discussion e1001833. doi: 10.1371/journal.pmed.1001833. eCollection 2015 Jun. PLoS Med. 2015. PMID: 26035291 Free PMC article. Clinical Trial.
References
-
- Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63(4):375–382. - PubMed
-
- Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63(4):385–390. - PubMed
-
- Rubinow D, Schmidt P. The neurobiology of menstrual cycle-related mood disorders. In: Charney D, Nestler E, Bunneyu B, editors. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999. pp. 907–914.
-
- McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20(3):279–307. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AG012553/AG/NIA NIH HHS/United States
- AG012554/AG/NIA NIH HHS/United States
- AG012539/AG/NIA NIH HHS/United States
- AG012531/AG/NIA NIH HHS/United States
- U01 AG012495/AG/NIA NIH HHS/United States
- U01 AG012505/AG/NIA NIH HHS/United States
- AG012535/AG/NIA NIH HHS/United States
- AG012546/AG/NIA NIH HHS/United States
- NR004061/NR/NINR NIH HHS/United States
- U01 AG012554/AG/NIA NIH HHS/United States
- U01 AG012535/AG/NIA NIH HHS/United States
- U01 AG012553/AG/NIA NIH HHS/United States
- U01 NR004061/NR/NINR NIH HHS/United States
- U01 AG012539/AG/NIA NIH HHS/United States
- AG012495/AG/NIA NIH HHS/United States
- U01 AG012546/AG/NIA NIH HHS/United States
- U01 AG012531/AG/NIA NIH HHS/United States
- AG012505/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases